Futura Medical Plc - Company Profile
Powered by 
All the sales intelligence you need on Futura Medical Plc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Futura Medical Plc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Futura Medical Plc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Futura Medical Plc (Futura Medical) is a pharmaceutical company. It is focused on developing and globally commercializing innovative sexual health products. The company’s product portfolio includes Eroxon for the treatment of erectile dysfunction (ED). Eroxon is an over-the-counter topical gel for ED, approved in markets, including Europe and the US. It allows men to achieve an erection within ten minutes. Haleon manages Eroxon's commercialization in the US, while Cooper Consumer Health oversees Europe, the UK, and Switzerland; M8 Pharmaceuticals handles Central and South America, and Labatec Pharma manages the Gulf Cooperation Council region and the Middle East. Futura Medical is headquartered in Surrey, England, the UK.
Headquarters
United Kingdom
Address
40 Occam Road, Guildford, Surrey, England, GU27YG
Website
www.futuramedical.com
Telephone
44 1483 685670
No of Employees
12
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
FUM (LON)
Revenue (2024)
$17.8M
349.1%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
119.9%
(2024 vs 2023)
Market Cap*
$4.3M
Net Profit Margin (2024)
XYZ
104.4%
(2024 vs 2023)
* As of and is in US$
Futura Medical Plc premium industry data and analytics
Products and Services
| Products |
|---|
| Eroxon: Erectile Dysfunction |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Patent Grant | In March, the company announced that the US Patent Office formally granted continuation of patent extending US protection for Eroxon (including derivatives) and WSD4000 through 2040. |
| 2023 | Regulatory Approval | In June, the company received US Food and Drug Administration approval for Eroxon, a first-of-its-kind treatment for erectile dysfunction that will not require a prescription. |
| 2022 | Contracts/Agreements | In February, the company entered into an agreement with Cooper Consumer Health to launch its erectile dysfunction gel in Europe. |
Competitor Comparison
| Key Parameters | Futura Medical Plc | Eli Lilly and Co | Pfizer Inc | Bayer AG | Teva Pharmaceutical Industries Ltd |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | United States of America | United States of America | Germany | Israel |
| City | Surrey | Indianapolis | New York City | Leverkusen | Tel Aviv |
| State/Province | England | Indiana | New York | Nordrhein-Westfalen | Tel Aviv |
| No. of Employees | 12 | 47,000 | 81,000 | 92,815 | 31,173 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Alex Duggan | Director; Chief Executive Officer | Executive Board | 2025 | 56 |
| Angela Hildreth | Secretary; Chief Operating Officer; Director - Finance | Executive Board | 2018 | 46 |
| Andrew Unitt | Chairman | Non Executive Board | 2022 | 69 |
| Ken James | Head-R&D; Director | Executive Board | 2016 | 74 |
| Roy Davis | Director | Non Executive Board | 2024 | 70 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer